 LA JOLLA, Calif., Aug. 16, 2021 PRNewswire -- Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates AOCsTM, today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy FSHD Clinical Trial Research Network FSHD CTRN to support a natural history study for people living with FSHD called the Motor Outcomes to Validate Evaluations Plus MOVE Study. 